Shanu Modi

Aug 2, 2024 | nature.com | Antonio Marra |Sarat Chandarlapaty |Shanu Modi

Correction to: Nature Reviews Clinical Oncology https://doi.org/10.1038/s41571-023-00849-9, published online 8 January 2024. In the version of the article initially published, there was an error in the second paragraph of the introduction, where “mouse erbB2” has been corrected to “human HER2” in the sentence now reading “Among these, a mouse mAb targeting human HER2 demonstrated remarkable preclinical activity…” in the HTML and PDF versions of article.

Jan 8, 2024 | nature.com | Antonio Marra |Sarat Chandarlapaty |Shanu Modi

AbstractAmplification and/or overexpression of ERBB2, the gene encoding HER2, can be found in 15–20% of invasive breast cancers and is associated with an aggressive phenotype and poor clinical outcomes.

Jan 6, 2024 | taxguru.in | Shanu Modi

ABSTRACTRecently, the Hon’ble Supreme Court, while hearing a petition under Article 32, denounced the trend of petitioners circumventing alternative channels of appeal and submitting Article 32 petitions to the Supreme Court in an effort to directly contest summonses or request bail while pretending to be contesting the PMLA’s provision. This decision came after a review petition was filed against the Vijay Madanlal Choudhary judgement delivered on July 27, 2022.

Nov 15, 2023 | onclive.com | Shanu Modi

Shanu Modi, MD, breast oncologist, Memorial Sloan Kettering Cancer Center, discusses updated survival data from the phase 3 DESTINY-Breast04 trial (NCT03734029) evaluating fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) in patients with HER2-low metastatic breast cancer. The DESTINY-Breast04 study enrolled patients with unresectable and/or metastatic HER2-low breast cancer who were previously treated with 1 to 2 prior lines of chemotherapy in the metastatic setting, Modi details.